The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s allergy conjunctivitis market report forecasts the allergy conjunctivitis market size to grow to $2.93 Billion by 2027, with a CAGR (compound annual growth rate) of more than 5%.

Learn More On The Allergy Conjunctivitis Market Report 2023 – https://www.thebusinessresearchcompany.com/report/allergy-conjunctivitis-global-market-report

Allergy Conjunctivitis Market Size Forecast
The global allergy conjunctivitis market is expected to grow from $2.12 billion in 2022 to $2.27 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The allergy conjunctivitis market is expected to grow to $2.93 billion in 2027 at a CAGR of 5.1%.

North America held the largest allergy conjunctivitis market share.

Key Allergy Conjunctivitis Market Driver ­– Rise In Exposure To Air Pollutants And Chemicals
According to the United States Environmental Protection Agency (EPA), an independent executive agency of the United States federal government tasked with environmental protection, approximately 67 million tonnes of pollutants were released into the atmosphere in the United States in 2021. As a result, the rise in exposure to air pollutants and chemicals is propelling the allergy conjunctivitis market forward.

Request for A Sample Of The Global Allergy Conjunctivitis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8806&type=smp

Key Allergy Conjunctivitis Market Trend – Product Innovation
To strengthen their market position, major companies in the allergy conjunctivitis market are focusing on developing innovative and advanced products. For example, in February 2020, Alcon, a medical company based in the United States that specialises in eye care products, launched Pataday, an eye allergy drop. The Pataday brand contains the number one doctor-prescribed eye allergy itch relief ingredient as well as the first non-prescription once-daily allergy itch relief drop. Pataday Once Daily Relief and Pataday Twice Daily Relief will be commercially available in the United States in time for the start of the spring allergy season. These medications will be available in all major mass-market, drug, and grocery stores across the country (over 40,000 locations), as well as online. A multimillion-dollar media strategy is supporting the launch, which includes a national TV advertising campaign and a strong web presence to reach people with eye allergies.

Allergy Conjunctivitis Market Segment
1) By Drug Class: Antihistamines and Mast Cell Stabilizers, Corticosteroids, Other Drug Classes
2) By Disease Type: Mild, Severe
3) By Distribution Channel: Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies

Allergy Conjunctivitis Market Major Players and Strategies
Major players in the allergy conjunctivitis market are Allergan plc., Santen Pharmaceutical Co Ltd., Bausch & Lomb Incorporated, Novartis AG, Sun Pharmaceutical Industries Ltd., Ocular Therapeutix Inc., Alcon, Eton Pharmaceutical, AbbVie Inc., Ajanta Pharma Limited, Akron Operating Company LLC, Alembic Pharmaceuticals Ltd., Cipla Ltd., Grevis Pharmaceutical Private Limited, Indoco RemediesLtd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd., Auven Therapeutics, and Atopix Therapeutics Ltd.

Santen Holdings U.S. Inc., a US-based pharmaceutical company and subsidiary of Santen Pharmaceutical, a Japan-based pharmaceutical company specialising in ophthalmology, paid $225 million for Eyevance Pharmaceuticals LLC in September 2020. Santan will be able to expand its global reach and enter the US pharmaceuticals industry as a result of this acquisition. Eyevance Pharmaceuticals LLC is a pharmaceutical company based in the United States that develops and commercialises topical ophthalmic products for the ocular surface and anterior segment.

The Allergy Conjunctivitis Global Market Report 2023 covers regional data on allergy conjunctivitis market size, allergy conjunctivitis market trends and drivers, opportunities, strategies, and allergy conjunctivitis market competitor analysis. The countries covered in the allergy conjunctivitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Allergy conjunctivitis is an inflammation of the conjunctiva caused by an allergic reaction to pollen or mould spores. The membrane or tissue that covers the inside of the eyelids as well as the white part of the eyeball is known as conjunctiva. Red, itchy, and watery eyes are signs of allergic conjunctivitis.

View More Reports Related To The Allergy Conjunctivitis Market –
Antimicrobial Susceptibility Testing Global Market Report 2023
Diagnostic And Monitoring Ophthalmic Devices And Equipment Global Market Report 2023
Healthcare Services Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: